CN-122005604-A - Application of codonopsis pilosula polysaccharide in preparation of aortic expansion prevention and treatment products

Abstract

The invention discloses application of codonopsis pilosula polysaccharide in preparing a product for preventing and treating aortic expansion, wherein the codonopsis pilosula polysaccharide is used for treating aortic expansion, and can remarkably improve survival rate of aortic expansion mice, inhibit aortic expansion formation, reduce collagen deposition in aortic neutral membrane, reduce glycosaminoglycan accumulation in aortic neutral membrane and reduce aortic diameter. The invention provides a new thought for developing novel aortic expansion prevention and treatment medicaments, and has potential clinical application value and social significance.

Inventors

• LUO YONGTING
• LUO JUNJIE
• AN PENG
• LUO XINYU
• WEI ZHIQIAN
• ZHU YINHUA
• ZHANG LIWEI

Assignees

• 中国农业大学

Dates

Publication Date

20260512

Application Date

20260228

Claims (10)

1. 1. Use of Codonopsis pilosula polysaccharide in preparing product for preventing and/or treating aortic dilatation is provided.
2. 2. The application of claim 1, wherein the application comprises at least one of: (1) Use in the preparation of a product for increasing survival in the case of aortic dilation; (2) Use in the manufacture of a product for inhibiting aortic dilation and/or aortic dissection; (3) Use in the preparation of a product for reducing collagen deposition in the neutral membrane of the aorta; (4) Use in the preparation of a product for reducing glycosaminoglycan accumulation in the neutral membrane of the aorta; (5) Use in the preparation of a product for reducing the diameter of the aorta.
3. 3. The use according to claim 2, wherein the use in the manufacture of a product for inhibiting aortic dilation and/or aortic dissection comprises: (2-1) use in the manufacture of a product for reducing the diameter of the aorta; (2-2) use in the manufacture of a product for reducing the degree of aortic arch expansion.
4. 4. The use according to claim 1, wherein the aortic expansion is β -aminopropionitrile induced aortic expansion.
5. 5. The use according to claim 1, wherein the product is a medicament.
6. 6. The use according to claim 5, wherein the only active ingredient in the medicament is codonopsis pilosula polysaccharide.
7. 7. The use according to claim 5, wherein the product further comprises excipients in the medicament which allow addition.
8. 8. The use according to claim 7, wherein the auxiliary material comprises isotonic agents, buffers, flavouring agents, excipients, fillers, binders, disintegrants or lubricants.
9. 9. The use according to claim 5, wherein the route of administration of the medicament comprises intravenous injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, oral administration, sublingual administration, nasal administration or nebulization.
10. 10. The use according to claim 1, wherein the daily amount of codonopsis pilosula polysaccharide is 8-25 mg/kg.

Description

Application of codonopsis pilosula polysaccharide in preparation of aortic expansion prevention and treatment products Technical Field The invention belongs to the technical field of biological medicines, and particularly relates to application of codonopsis pilosula polysaccharide in preparation of products for preventing and treating aortic dilatation. Background Aortic dilation is a life-threatening disease caused by a tear in the intimal layer of the aorta or hemorrhage in the aortic wall, resulting in separation (dilation) of the layers of the aortic wall. As blood flows into the aortic wall, the intimal flap may extend forward and backward from the original tear or bleeding site and may progress to the side branch artery. The first two weeks after aortic expansion is considered the acute phase, and patients are extremely susceptible to life-threatening complications and death. The treatment method of aortic expansion mainly comprises medication treatment, interventional treatment and surgical operation treatment, and although the treatment has greatly advanced at present, the operation difficulty of aortic expansion is high, complications such as multi-organ functional injury and coagulation dysfunction after operation are still not completely avoided, and the blood vessel after operation can be further degenerative lesion and is at risk of secondary operation and rupture. Thus, prophylactic drugs against patients with acute aortic expansion remain a hotspot in current clinical studies. Radix Codonopsis is an important tonic in traditional Chinese medicine, belonging to the family of Campanulaceae. The medicinal part of pilose asiabell root is dry root and is mainly produced in China. The planting history can be traced to ancient times, and the Chinese medicinal composition can be widely applied to the clinic of traditional Chinese medicine as an qi replenishing medicament, and is often used for treating symptoms such as qi deficiency, cough, asthma, internal heat, thirst and the like. The radix Codonopsis polysaccharide is one of core active ingredients extracted from radix Codonopsis, has effects of resisting tumor, inflammation, oxidation, neuroprotection, enhancing immunity, relieving fatigue, lowering blood sugar, etc., and has multi-target and multi-channel regulating ability. As reported in the literature, the codonopsis pilosula polysaccharide is used as a functional food, and can effectively delay cell aging and protect cardiovascular health. At present, related literature reports of the codonopsis pilosula polysaccharide for preventing and treating aortic expansion are not seen, so that the codonopsis pilosula polysaccharide has extremely high potential value and social significance in developing the codonopsis pilosula polysaccharide into a product for preventing and treating aortic expansion. Disclosure of Invention In order to better prevent and treat aortic dilation and fully mine the medicinal value of the codonopsis pilosula, the invention provides the following technical scheme. In a first aspect, the present invention provides the use of a Codonopsis pilosula polysaccharide in the manufacture of a product for the prevention and/or treatment of aortic dilation. Preferably, the application comprises at least one of: (1) Use in the preparation of a product for increasing survival in the case of aortic dilation; (2) Use in the manufacture of a product for inhibiting aortic dilation and/or aortic dissection; (3) Use in the preparation of a product for reducing collagen deposition in the neutral membrane of the aorta; (4) Use in the preparation of a product for reducing glycosaminoglycan accumulation in the neutral membrane of the aorta. Preferably, the use in the manufacture of a product for inhibiting aortic dilation and/or aortic dissection comprises: (2-1) use in the manufacture of a product for reducing the diameter of the aorta; (2-2) use in the manufacture of a product for reducing the degree of aortic arch expansion. Preferably, the aortic expansion is beta-aminopropionitrile induced aortic expansion. Preferably, the daily dosage of the codonopsis pilosula polysaccharide is 8-25 mg/kg, for example, 8, 10, 12, 16, 18, 20, 22, 25 mg/kg. Furthermore, the daily dosage of the codonopsis pilosula polysaccharide is 10-20 mg/kg. Preferably, the product is a medicament. Furthermore, the only active ingredient in the medicine is codonopsis pilosula polysaccharide. Further, the dosage forms of the medicine comprise tablets, aqueous solution injection, powder injection, granules, pills, powder, suppositories, emulsions, gels, aerosols, sprays, powder mists, capsules or oral liquids. Further, the administration route of the drug includes intravenous injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, oral administration, sublingual administration, nasal administration or nebulization. Preferably, the medicament further comprises auxiliary materials which are a